<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Bevacizumab is largely used in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>Postsurgical healing complications have been described for patients following treatment with Bevacizumab </plain></SENT>
<SENT sid="2" pm="."><plain>We report three cases of spontaneous intestinal <z:mpath ids='MPATH_81'>perforation</z:mpath> following infusion of Bevacizumab </plain></SENT>
<SENT sid="3" pm="."><plain>From January 2002 through October 2010, Bevacizumab was delivered in 143 patients </plain></SENT>
<SENT sid="4" pm="."><plain>Spontaneous intestinal <z:mpath ids='MPATH_81'>perforation</z:mpath> occurred in 3 cases (2.1Â %) </plain></SENT>
<SENT sid="5" pm="."><plain>Bevacizumab may result in severe complications </plain></SENT>
<SENT sid="6" pm="."><plain>Therefore, it is important to consider every patient treated with Bevacizumab at risk for life-threatening gastro-intestinal complications </plain></SENT>
</text></document>